semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-26. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
研究兴趣主要集中在神经营养因子相关的路径上，包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升，但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验，人体对照研究数量有限。因此，该化合物的作用机制在文献中属于活跃讨论，而非已经确立的定论。
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
In the past, Chipotle mainly relied on billboards, radio advertisements, and word of mouth to advertise. In 2010, the company initiated an ad campaign that mocks advice given to Chipotle by advertising agencies. In 2012, Chipotle aired its first nationally televised commercial during the 54th Annual Grammy Awards ceremony. Chipotle has run many promotions giving out free food to potential customers, especially when opening a new store. Stores also give out free burritos on certain holidays; for instance, on Halloween, some locations have had promotions in which free burritos are given to people who come dressed as a burrito. Chipotle gave away free burritos to reporters during the 1997 trial of Timothy McVeigh, which took place in Chipotle's hometown of Denver. In addition, stores offered free burritos to those displaced by Hurricane Katrina. Chipotle received attention when Ozzy Osbourne's reality show The Osbournes featured the company's burritos heavily. For Halloween 2010, Chipotle announced that customers dressed as a processed food product would receive a burrito for $2. The event was part of a $1 million fundraiser for Jamie Oliver's Food Revolution called "Boorito 2010: The Horrors of Processed Food". Also in support of family farms, Chipotle released music videos of Karen O of the Yeah Yeah Yeahs and Willie Nelson. On September 12, 2013, Chipotle released an animated short called The Scarecrow, with a companion mobile video game; both feature a narrative heavily critical of industrial farming, but little in the way of direct marketing for the chain.
=== Etymology === The word submarine means 'underwater' or 'under-sea' (as in submarine canyon, submarine pipeline) though as a noun it generally refers to a vessel that can travel underwater. The term is a contraction of submarine boat and occurs as such in several languages, e.g. French (sous-marin), and Spanish (submarino), although others retain the original term, such as Dutch (Onderzeeboot), German (Unterseeboot), Swedish (Undervattensbåt), and Russian (подводная лодка: podvodnaya lodka), all of which mean 'submarine boat'. By naval tradition, submarines are usually referred to as boats rather than as ships, regardless of their size. Although referred to informally as boats, U.S. submarines employ the designation USS (United States Ship) at the beginning of their names, such as USS Alabama. In the Royal Navy, the designation HMS can refer to "His Majesty's Ship" or "His Majesty's Submarine", though the latter is sometimes rendered "HMS/m".
==== Hybrid Closed Loop (HCL) / Advanced Hybrid Closed Loop (AHCL) ==== Hybrid closed loop (HCL) systems further expand on the capabilities of PLGS systems by adjusting basal insulin delivery rates both up and down in response to values from a continuous glucose monitor. Through this modulation of basal insulin, the system is able to reduce the magnitude and duration both hyperglycemic and hypoglycemic events. Users still must initiate manual mealtime boluses. Advanced hybrid closed loop systems have advanced algorithms. Fully Closed Loop (FCL) Fully or full closed loop (FCL) systems adjust insulin delivery in response to changes in glucose levels without requiring input by users for mealtime insulin or announcements of meals.
Förster resonance energy transfer (FRET)-based Cl indicators consist of two fluorescent proteins, Cyan fluorescent protein (CFP) and YFP connected via a polypeptide linker. This allows ratiometric Cl− measurements based on the Cl− sensitivity of YFP and Cl− insensivity of CFP. Clomeleon and Cl− Sensor are FRET-based Cl indicators that allow ratiometric non-invasive monitoring of chloride activity in living cells.
=== Nuclear bomb fallout === Bombs in the Arctic area of Novaja Zemlja and bombs detonated in or near the stratosphere released caesium-137 that landed in upper Lapland, Finland. Measurements of caesium-137 in the region in the 1960s were reportedly 45,000 becquerels. Figures from 2011 have a midrange of about 1,100 becquerels, but no increase in cancer cases has been identified.
Sources: en.wikipedia.org
The NDA for gemigliptin was submitted to the Korea Food & Drug Administration (KFDA) in July 2011, and it was approved in June 2012. By the end of 2012, gemigliptin will be marketed in Korea as Zemiglo which is the fifth new DPP-4 inhibitor diabetes treatment in the world. Sanofi-Synthelabo India Private Limited announced the launch of drug for type 2 diabetes patients in India: Zemiglo (gemigliptin) in July 2016. Zemiglo is a once daily, oral tablet. As per the International Diabetes Federation Diabetes Atlas 2015, India is home to the second largest number of adults living with diabetes worldwide, after China, with 69.1 million patients and expected to rise to 1401 million in 2040. India is the largest contributor to South East Asia regional mortality, with 1 million deaths attributable to diabetes. These statistics reveal how diabetes is fast gaining the status of a potential epidemic in India and establishes the need for treatment compliance and effective control through diet, exercise and drugs for long-term positive effects in disease management.
== Natural extract == Combretum indicum (Quisqualis indica var. villosa) is native to tropical Asia but is still doubt whether is indigenous from Africa or was introduced there. Since the amino acid that can be isolated from its fruits can nowadays be made in the lab, the plant is mostly cultivated as an ornamental plant. In natural medicine tradition Quisqualis indica has an anthelmintic effect, therefore they are used to treat round worm infection. Quisqualic acid resembles the action of the anthelmintic α-santonin, so in some countries the seeds of the plants are used to substitute for the drug. However, the acid has shown excitatory effects on cultured neurons, as well as in a variety of animal models, as it causes several types of limbic seizures and neuronal necrosis. The quisqualic acid can be now commercially synthesized, and it functions as an antagonist for its receptor, found in the mammalian central nervous system.
It is generally incorrect to state that Cauchy stress is a function of merely a strain tensor, as such a model lacks crucial information about material rotation needed to produce correct results for an anisotropic medium subjected to vertical extension in comparison to the same extension applied horizontally and then subjected to a 90-degree rotation; both these deformations have the same spatial strain tensors yet must produce different values of the Cauchy stress tensor. Even though the stress in a Cauchy-elastic material depends only on the state of deformation, the work done by stresses might depend on the path of deformation. Therefore, Cauchy elasticity includes non-conservative "non-hyperelastic" models (in which work of deformation is path dependent) as well as conservative "hyperelastic material" models (for which stress can be derived from a scalar "elastic potential" function).
Genentech pioneered the use of recombinant human growth hormone for human therapy, which was approved by the FDA in 1985. Prior to its production by recombinant DNA technology, growth hormone used to treat deficiencies was extracted from the pituitary glands of cadavers. Attempts to create a wholly synthetic HGH failed. Limited supplies of HGH resulted in the restriction of HGH therapy to the treatment of idiopathic short stature. Very limited clinical studies of growth hormone derived from an Old World monkey, the rhesus macaque, were conducted by John C. Beck and colleagues in Montreal, in the late 1950s. The study published in 1957, which was conducted on "a 13-year-old male with well-documented hypopituitarism secondary to a crainiophyaryngioma," found that: "Human and monkey growth hormone resulted in a significant enhancement of nitrogen storage ... (and) there was a retention of potassium, phosphorus, calcium, and sodium. ... There was a gain in body weight during both periods. ... There was a significant increase in urinary excretion of aldosterone during both periods of administration of growth hormone. This was most marked with the human growth hormone. ... Impairment of the glucose tolerance curve was evident after 10 days of administration of the human growth hormone.
Sources: en.wikipedia.org
Development, implementation, analysis and reporting Leading quality improvement initiatives based on audit findings. An example from the UK is the National Comparative Audit of Blood Transfusion (NCABT), which is a programme of clinical audits that look at the use and administration of blood and blood components in the National Health System (NHS) and independent hospitals in the UK. This audit programme's objectives are to provide evidence that blood is being prescribed and used appropriately and administered safely. It also highlights where practice is deviating from the guidelines and how this might affect patient outcomes. Data collection for these audits can be undertaken by a variety of health care professionals within the participating organisations, however the majority of the data collection and data submission is undertaken by the TP.
In 1995, the largest sperm bank in New York State was ordered to close (and no longer operate semen banks and blood banks), over the objections of its owner the Daxor Corporation and its president, CEO, and majority shareholder Joseph Feldschuh, by New York State Supreme Court Justice Harold Tompkins. The Justice found that Daxor had repeatedly endangered the public health over several years. A 1993 inspection had documented 517 violations by the sperm bank, including its failure to screen sperm donors properly for sexually transmitted diseases. Rather, the inspection showed that Daxor had, in fact, made available semen from men who had tested positive for hepatitis, chlamydia, and gonorrhea. Daxor employees told government investigators that Feldschuh had instructed them to make false entries on business records and to lie to investigators. Feldschuh claimed New York State Health Department officials were conspiring to shut down his business, sued them three times, appealed three times, and lost each of the six times. The Daxor sperm bank was sued for negligence by customers. In one case, a White mother sued the sperm bank because though her White terminally ill husband's sperm had been stored at the sperm bank, when she asked for the sperm and used it to artificially inseminate her, she ended up giving birth to a Black baby. In 2007 another mother settled her own claims against Daxor for $250,000, which she said was a fraction of the estimated $7 million in care that will be needed for both of her children.
Insulin receptor substrates (IRS) are important ligands in the insulin response of human cells. IRS-1, for example, is an IRS protein that contains a phosphotyrosine binding-domain (PTB-domain). In addition, the insulin receptor contains a NPXY motif. The PTB-domain binds the NPXY sequence. Thus, the insulin receptor binds IRS.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.